Patents by Inventor Akira Kugimiya
Akira Kugimiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11638717Abstract: The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.Type: GrantFiled: March 28, 2018Date of Patent: May 2, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Akira Kugimiya, Mitsuaki Sekiguchi, Norikazu Kuroda, Jun Nakamura, Tetsuya Tanino, Yasunori Mitsuoka, Takeshi Kasuya, Yasuharu Kato
-
Patent number: 11041152Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.Type: GrantFiled: April 13, 2017Date of Patent: June 22, 2021Assignees: E-NA BIOTEC INC.Inventors: Yukihiro Akao, Yukio Kitade, Mitsuaki Sekiguchi, Yasunori Mitsuoka, Akira Kugimiya, Yasuo Sasaki
-
Patent number: 10940201Abstract: The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.Type: GrantFiled: February 28, 2018Date of Patent: March 9, 2021Assignee: SHIONOGI & CO., LTD.Inventors: Akira Kugimiya, Tetsuya Tanino, Mitsuaki Sekiguchi, Yasunori Mitsuoka, Norikazu Kuroda, Jun Nakamura
-
Publication number: 20200384010Abstract: The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.Type: ApplicationFiled: March 28, 2018Publication date: December 10, 2020Applicant: SHIONOGI & CO., LTD.Inventors: Akira KUGIMIYA, Mitsuaki SEKIGUCHI, Norikazu KURODA, Jun NAKAMURA, Tetsuya TANINO, Yasunor MITSUOKA, Takeshi KASUYA, Yasuharu KATO
-
Publication number: 20190119677Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.Type: ApplicationFiled: April 13, 2017Publication date: April 25, 2019Applicant: Shionogi & Co., Ltd.Inventors: Yukihiro AKAO, Yukio KITADE, Mitsuaki SEKIGUCHI, Yasunori MITSUOKA, Akira KUGIMIYA, Yasuo SASAKI
-
Publication number: 20180291013Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: ApplicationFiled: November 3, 2017Publication date: October 11, 2018Inventors: Motonari UESUGI, Salih J. Wakil, Lutfi ABU-ELHEIGA, Qian MAO, Shinji KAMISUKI, Akira KUGIMIYA, Mizuki WATANABE
-
Publication number: 20180264105Abstract: The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.Type: ApplicationFiled: February 28, 2018Publication date: September 20, 2018Applicant: Shionogi & Co., Ltd.Inventors: Akira KUGIMIYA, Tetsuya TANINO, Mitsuaki SEKIGUCHI, Yasunori MITSUOKA, Norikazu KURODA, Jun NAKAMURA
-
Patent number: 9440938Abstract: The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; R1 is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; L1 is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.Type: GrantFiled: February 19, 2015Date of Patent: September 13, 2016Assignee: SHIONOGI & CO., LTD.Inventors: Akira Kugimiya, Masahiko Fujioka, Yuki Tachibana, Takami Murashi, Naohiro Onodera
-
Publication number: 20160257675Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: ApplicationFiled: May 24, 2016Publication date: September 8, 2016Inventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Qian Mao, Shinji Kamisuki, Akira Kugimiya, Mizuki Watanabe
-
Publication number: 20160221999Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: ApplicationFiled: March 4, 2016Publication date: August 4, 2016Inventors: Motonari UESUGI, Salih J. Wakil, Lutfi ABU-ELHEIGA, Qian MAO, Shinji KAMISUKI, Akira KUGIMIYA, Mizuki WATANABE
-
Patent number: 9315535Abstract: The present invention provides compounds shown by the formula: wherein Y1 is CR6 or N, Y2 is CR7 or N, Y3 is CR8 or N, R6, R7 and R8 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.Type: GrantFiled: February 17, 2014Date of Patent: April 19, 2016Assignee: SHIONOGI & CO., LTD.Inventors: Yasunori Mitsuoka, Akira Kugimiya, Aiko Yamashita
-
Publication number: 20150368287Abstract: The present invention provides compounds shown by the formula: wherein Y1 is CR6 or N, Y2 is CR7 or N, Y3 is CR8 or N, R6, R7 and R8 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.Type: ApplicationFiled: February 17, 2014Publication date: December 24, 2015Applicant: SHIONOGI & CO., LTD.Inventors: Yasunori MITSUOKA, Akira KUGIMIYA, Aiko YAMASHITA
-
Publication number: 20150158833Abstract: The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; R1 is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; L1 is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.Type: ApplicationFiled: February 19, 2015Publication date: June 11, 2015Inventors: Akira KUGIMIYA, Masahiko FUJIOKA, Yuki TACHIBANA, Takami MURASHI, Naohiro ONODERA
-
Patent number: 8993763Abstract: The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; R1 is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; L1 is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.Type: GrantFiled: September 25, 2006Date of Patent: March 31, 2015Assignee: Shionogi & Co., Ltd.Inventors: Akira Kugimiya, Masahiko Fujioka, Yuki Tachibana, Takami Murashi, Naohiro Onodera
-
Patent number: 8957219Abstract: Disclosed is a compound which is useful as an endothelial lipase inhibitor.Type: GrantFiled: October 15, 2009Date of Patent: February 17, 2015Assignee: Shionogi & Co., Ltd.Inventors: Koji Masuda, Shiro Kida, Kyohei Hayashi, Manabu Katou, Naoki Yoshikawa, Akira Kugimiya, Mado Nakajima, Nobuyuki Tanaka
-
Patent number: 8927578Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: GrantFiled: May 31, 2012Date of Patent: January 6, 2015Assignee: Baylor College of MedicineInventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Qian Mao, Shinji Kamisuki, Akira Kugimiya
-
Publication number: 20140288302Abstract: A pharmaceutical composition including a compound of formula (I): its pharmaceutically acceptable salt, or a solvate thereof. Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by formula: —C(R1R2)—C(?O)—NR3R4 and a group represented by formula: —R5, a broken line represents presence or absence of a bond, Z is —NR6—, ?N—, —O—, or —S—, R6 is halogen or substituted or unsubstituted alkyl, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen or substituted or unsubstituted alkyl, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.Type: ApplicationFiled: March 18, 2014Publication date: September 25, 2014Applicant: Shionogi & Co., Ltd.Inventors: Koji MASUDA, Shiro KIDA, Kyohei HAYASHI, Manabu KATOU, Naoki YOSHIKAWA, Akira KUGIMIYA, Mado NAKAJIMA, Nobuyuki TANAKA
-
Patent number: 8778976Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: GrantFiled: May 31, 2012Date of Patent: July 15, 2014Assignee: Baylor College of MedicineInventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Qian Mao, Shinji Kamisuki, Akira Kugimiya
-
Patent number: 8623903Abstract: The present invention provides an indolecarboxylic acid derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (I): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of —X1?X2—X3?X4— is a formula of —C(R1)?C(R2)—C(R3)?C(R4)— etc.; X5 is C(R5) or N; R1, R2, R3, R4 and R5 is independently a hydrogen atom, a halogen atom etc; R6 is a formula of —Z—R10 etc. wherein Z is alkylene etc., and R10 is carboxy etc.; R7 is optionally substituted alkyloxy etc.; R8 is independently a halogen atom etc.; R9 is independently optionally substituted alkyl etc.; Y is a single bond etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or a solvate thereof.Type: GrantFiled: February 8, 2012Date of Patent: January 7, 2014Assignee: Shionogi & Co., Ltd.Inventors: Akira Kugimiya, Yuki Tachibana
-
Publication number: 20130012538Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.Type: ApplicationFiled: May 31, 2012Publication date: January 10, 2013Applicant: Baylor College of MedicineInventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Qian Mao, Shinji Kamisuki, Akira Kugimiya